BVX-M001: Phase IIa started

BiondVax began a double-blind, placebo-controlled, Israeli Phase IIa trial to evaluate 500 µg adjuvanted Multimeric-001 injection vs. adjuvanted and non-adjuvanted placebo solution in 200 healthy volu...